Crestchem（526269）株式概要クレストケム社はインドで栄養化学製品の製造、マーケティング、輸出を行っている。 詳細526269 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績3/6財務の健全性5/6配当金3/6報酬当社が推定した公正価値より67.3%で取引されている リスク分析意味のある時価総額がありません ( ₹390M )意味のある収益がありません ( ₹266M )Indian市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見る526269 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹130.0045.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-2m892m2016201920222025202620282031Revenue ₹892.4mEarnings ₹74.6mAdvancedSet Fair ValueView all narrativesCrestchem Limited 競合他社Roopa IndustriesSymbol: BSE:530991Market cap: ₹424.5mAmbica Agarbathies Aroma & IndustriesSymbol: BSE:532335Market cap: ₹401.6mGujarat PetrosyntheseSymbol: BSE:506858Market cap: ₹334.3mDynamic IndustriesSymbol: BSE:524818Market cap: ₹333.1m価格と性能株価の高値、安値、推移の概要Crestchem過去の株価現在の株価₹130.0052週高値₹195.0052週安値₹73.01ベータ0.591ヶ月の変化35.44%3ヶ月変化42.29%1年変化-31.22%3年間の変化88.27%5年間の変化293.94%IPOからの変化1,148.80%最新ニュースお知らせ • May 18Crestchem Limited to Report Q4, 2026 Results on May 26, 2026Crestchem Limited announced that they will report Q4, 2026 results on May 26, 2026Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹119, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 18% over the past three years.New Risk • Apr 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$10m (₹233.3m market cap, or US$2.49m). Minor Risk Revenue is less than US$5m (₹266m revenue, or US$2.8m).Recent Insider Transactions • Feb 27Chairman & MD recently bought ₹69k worth of stockOn the 23rd of February, Dipak Patel bought around 750 shares on-market at roughly ₹91.45 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹80k. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹533k worth in shares.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹2.39 (vs ₹1.74 in 3Q 2025)Third quarter 2026 results: EPS: ₹2.39 (up from ₹1.74 in 3Q 2025). Revenue: ₹73.4m (up 53% from 3Q 2025). Net income: ₹7.17m (up 38% from 3Q 2025). Profit margin: 9.8% (down from 11% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹95.46, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 49% over the past three years.最新情報をもっと見るRecent updatesお知らせ • May 18Crestchem Limited to Report Q4, 2026 Results on May 26, 2026Crestchem Limited announced that they will report Q4, 2026 results on May 26, 2026Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹119, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 18% over the past three years.New Risk • Apr 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$10m (₹233.3m market cap, or US$2.49m). Minor Risk Revenue is less than US$5m (₹266m revenue, or US$2.8m).Recent Insider Transactions • Feb 27Chairman & MD recently bought ₹69k worth of stockOn the 23rd of February, Dipak Patel bought around 750 shares on-market at roughly ₹91.45 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹80k. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹533k worth in shares.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹2.39 (vs ₹1.74 in 3Q 2025)Third quarter 2026 results: EPS: ₹2.39 (up from ₹1.74 in 3Q 2025). Revenue: ₹73.4m (up 53% from 3Q 2025). Net income: ₹7.17m (up 38% from 3Q 2025). Profit margin: 9.8% (down from 11% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹95.46, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 49% over the past three years.お知らせ • Feb 07Crestchem Limited to Report Q3, 2026 Results on Feb 13, 2026Crestchem Limited announced that they will report Q3, 2026 results on Feb 13, 2026New Risk • Feb 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹269.3m market cap, or US$2.98m). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Profit margins are more than 30% lower than last year (8.3% net profit margin). Revenue is less than US$5m (₹243m revenue, or US$2.7m).Reported Earnings • Nov 14Second quarter 2026 earnings releasedSecond quarter 2026 results: Revenue: ₹73.4m (down 6.0% from 2Q 2025). Net income: ₹5.45m (down 45% from 2Q 2025). Profit margin: 7.4% (down from 13% in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 04Crestchem Limited to Report First Half, 2026 Results on Nov 12, 2025Crestchem Limited announced that they will report first half, 2026 results on Nov 12, 2025お知らせ • Aug 06Crestchem Limited to Report Q1, 2026 Results on Aug 12, 2025Crestchem Limited announced that they will report Q1, 2026 results on Aug 12, 2025Reported Earnings • Jul 31Full year 2025 earnings released: EPS: ₹9.09 (vs ₹7.15 in FY 2024)Full year 2025 results: EPS: ₹9.09 (up from ₹7.15 in FY 2024). Revenue: ₹250.8m (up 18% from FY 2024). Net income: ₹27.3m (up 27% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 60% per year whereas the company’s share price has increased by 59% per year.Board Change • Jul 31High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Chairman & MD Dipak Patel is the most experienced director on the board, commencing their role in 2008. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jul 23+ 1 more updateCrestchem Limited Announces Resignation of Khyati Vyas as CFO, Effective July 1, 2025Crestchem Limited announced the resignation of Khyati Vyas as CFO with effect from July 01, 2025, due to her health problems.お知らせ • Jun 24Crestchem Limited, Annual General Meeting, Aug 21, 2025Crestchem Limited, Annual General Meeting, Aug 21, 2025, at 12:15 Indian Standard Time.Reported Earnings • May 29Full year 2025 earnings released: EPS: ₹9.09 (vs ₹7.15 in FY 2024)Full year 2025 results: EPS: ₹9.09 (up from ₹7.15 in FY 2024). Revenue: ₹255.2m (up 20% from FY 2024). Net income: ₹27.3m (up 27% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 60% per year whereas the company’s share price has increased by 58% per year.お知らせ • May 28Crestchem Limited Recommends Final Dividend for the Financial Year Ended March 31, 2025Crestchem Limited recommended a final dividend at INR 1.00 (10%) per equity share of face value of INR 10 each for the financial year ended March 31, 2025. The said final dividend, if approved by the members of the Company at the upcoming Annual General Meeting (`AGM') of the Company, will be paid/dispatched within stipulated time period of its declaration at the said AGM of the Company.お知らせ • May 20Crestchem Limited to Report Q4, 2025 Results on May 28, 2025Crestchem Limited announced that they will report Q4, 2025 results on May 28, 2025Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹223, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 26x in the Chemicals industry in India. Total returns to shareholders of 433% over the past three years.Recent Insider Transactions • Mar 23Chairman & MD recently bought ₹80k worth of stockOn the 21st of March, Dipak Patel bought around 350 shares on-market at roughly ₹230 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹829k worth in shares.Valuation Update With 7 Day Price Move • Mar 06Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹216, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 441% over the past three years.Reported Earnings • Feb 14Third quarter 2025 earnings released: EPS: ₹1.74 (vs ₹3.03 in 3Q 2024)Third quarter 2025 results: EPS: ₹1.74 (down from ₹3.03 in 3Q 2024). Revenue: ₹48.0m (down 35% from 3Q 2024). Net income: ₹5.21m (down 43% from 3Q 2024). Profit margin: 11% (down from 12% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹306, the stock trades at a trailing P/E ratio of 29x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 636% over the past three years.お知らせ • Feb 04Crestchem Limited to Report Q3, 2025 Results on Feb 12, 2025Crestchem Limited announced that they will report Q3, 2025 results on Feb 12, 2025Recent Insider Transactions • Jan 02Chairman & MD recently bought ₹61k worth of stockOn the 27th of December, Dipak Patel bought around 250 shares on-market at roughly ₹244 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹176k. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹742k worth in shares.Valuation Update With 7 Day Price Move • Jan 01Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹294, the stock trades at a trailing P/E ratio of 35.2x. Average trailing P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 560% over the past three years.Valuation Update With 7 Day Price Move • Nov 18Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹264, the stock trades at a trailing P/E ratio of 31.6x. Average trailing P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 476% over the past three years.お知らせ • Oct 31Crestchem Limited to Report Q2, 2025 Results on Nov 12, 2024Crestchem Limited announced that they will report Q2, 2025 results on Nov 12, 2024Valuation Update With 7 Day Price Move • Oct 25Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹226, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 508% over the past three years.Valuation Update With 7 Day Price Move • Oct 10Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₹249, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 438% over the past three years.Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹190, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 36x in the Chemicals industry in India. Total returns to shareholders of 257% over the past three years.お知らせ • Sep 12Crestchem Limited Announces Resignation of Binaben Parasbhai Patel as Independent Director, Effective September 20, 2024Crestchem Limited announced resignation of Smt. Binaben Parasbhai Patel as Independent Director, w.e.f. September 20, 2024.Reported Earnings • Aug 07Full year 2024 earnings released: EPS: ₹7.15 (vs ₹2.31 in FY 2023)Full year 2024 results: EPS: ₹7.15 (up from ₹2.31 in FY 2023). Revenue: ₹212.6m (up 27% from FY 2023). Net income: ₹21.5m (up 210% from FY 2023). Profit margin: 10% (up from 4.1% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 07Crestchem Limited to Report Q1, 2025 Results on Aug 12, 2024Crestchem Limited announced that they will report Q1, 2025 results at 12:15 PM, Indian Standard Time on Aug 12, 2024Board Change • Jul 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Executive Independent Director Nitinkumar Shah was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Jul 10Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹144, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 161% over the past three years.お知らせ • Jul 05Crestchem Limited Announces Director ChangesCrestchem Limited at its board meeting held on July 4, 2024 announced appointment of Smt. Priyanka M. Patel as additional director effective from July 4, 2024. Further, the company announced Resignation of Shri Manojkumar B. Patel as Independent Director effective from July 04, 2024, Due to his preoccupations. And Shri Rajesh I Mody ceased to be Independent Director effective from July 4, 2024 as his tenure as Independent director is over.お知らせ • Jul 01Crestchem Limited, Annual General Meeting, Aug 30, 2024Crestchem Limited, Annual General Meeting, Aug 30, 2024.Recent Insider Transactions • Jun 25Chairman & MD recently bought ₹53k worth of stockOn the 22nd of June, Dipak Patel bought around 388 shares on-market at roughly ₹136 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹300k. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹811k worth in shares.Recent Insider Transactions • Jun 08Chairman & MD recently bought ₹300k worth of stockOn the 3rd of June, Dipak Patel bought around 2k shares on-market at roughly ₹143 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹758k worth in shares.お知らせ • May 30Crestchem Limited Recommends Final Maiden Dividend for the Financial Year Ended March 31, 2024Crestchem Limited at its Board meeting held on May 28, 2024, recommended a final maiden dividend at INR 0.50 (5%) per equity share of face value of INR 10 each for the financial year ended March 31, 2024. The final dividend, if approved by the members of the company at the upcoming Annual General Meeting of the Company, will be paid/dispatched within stipulated time period of its declaration at the said AGM of the Company.Reported Earnings • May 30Full year 2024 earnings released: EPS: ₹7.15 (vs ₹2.31 in FY 2023)Full year 2024 results: EPS: ₹7.15 (up from ₹2.31 in FY 2023). Revenue: ₹215.2m (up 29% from FY 2023). Net income: ₹21.5m (up 210% from FY 2023). Profit margin: 10.0% (up from 4.1% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 22Crestchem Limited to Report Q4, 2024 Results on May 28, 2024Crestchem Limited announced that they will report Q4, 2024 results on May 28, 2024Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹105, the stock trades at a trailing P/E ratio of 20.3x. Average trailing P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 277% over the past three years.Reported Earnings • Feb 14Third quarter 2024 earnings released: EPS: ₹3.03 (vs ₹0.72 in 3Q 2023)Third quarter 2024 results: EPS: ₹3.03 (up from ₹0.72 in 3Q 2023). Revenue: ₹74.2m (up 85% from 3Q 2023). Net income: ₹9.09m (up 322% from 3Q 2023). Profit margin: 12% (up from 5.4% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Nov 17Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹80.60, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 28% over the past three years.Reported Earnings • Nov 05Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: ₹45.5m (up 17% from 2Q 2023). Net income: ₹3.39m (up 176% from 2Q 2023). Profit margin: 7.5% (up from 3.2% in 2Q 2023). The increase in margin was driven by higher revenue.お知らせ • Oct 28Crestchem Limited to Report Q2, 2024 Results on Nov 04, 2023Crestchem Limited announced that they will report Q2, 2024 results on Nov 04, 2023Recent Insider Transactions • Sep 24Chairman & MD recently bought ₹111k worth of stockOn the 22nd of September, Dipak Patel bought around 2k shares on-market at roughly ₹62.47 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹116k. Despite this recent buy, Dipak has been a net seller over the last 12 months, reducing personal holdings by ₹152k.お知らせ • Aug 05Crestchem Limited to Report Q1, 2024 Results on Aug 12, 2023Crestchem Limited announced that they will report Q1, 2024 results on Aug 12, 2023Reported Earnings • Jul 30Full year 2023 earnings released: EPS: ₹2.31 (vs ₹1.89 in FY 2022)Full year 2023 results: EPS: ₹2.31 (up from ₹1.89 in FY 2022). Revenue: ₹168.8m (up 112% from FY 2022). Net income: ₹6.93m (up 22% from FY 2022). Profit margin: 4.1% (down from 7.1% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 83% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 07Crestchem Limited, Annual General Meeting, Aug 24, 2023Crestchem Limited, Annual General Meeting, Aug 24, 2023, at 12:15 Indian Standard Time.Valuation Update With 7 Day Price Move • Jun 01Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹88.04, the stock trades at a trailing P/E ratio of 35.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 91% over the past year.Valuation Update With 7 Day Price Move • May 18Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹80.65, the stock trades at a trailing P/E ratio of 32.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 95% over the past year.Valuation Update With 7 Day Price Move • Apr 19Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹101, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 863% over the past three years.Recent Insider Transactions • Mar 23Chairman & MD recently sold ₹226k worth of stockOn the 21st of March, Dipak Patel sold around 2k shares on-market at roughly ₹98.48 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Dipak has been a net seller over the last 12 months, reducing personal holdings by ₹378k.Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹112, the stock trades at a trailing P/E ratio of 44.7x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 917% over the past three years.Recent Insider Transactions • Mar 13Chairman & MD recently sold ₹166k worth of stockOn the 10th of March, Dipak Patel sold around 2k shares on-market at roughly ₹91.88 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Dipak has been a net seller over the last 12 months, reducing personal holdings by ₹152k.Valuation Update With 7 Day Price Move • Mar 08Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹83.83, the stock trades at a trailing P/E ratio of 33.5x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 629% over the past three years.Valuation Update With 7 Day Price Move • Feb 16Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹74.95, the stock trades at a trailing P/E ratio of 29.9x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 552% over the past three years.お知らせ • Jan 31Crestchem Limited to Report Q3, 2023 Results on Feb 11, 2023Crestchem Limited announced that they will report Q3, 2023 results on Feb 11, 2023Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹0.41 (vs ₹0.15 loss in 2Q 2022)Second quarter 2023 results: EPS: ₹0.41 (up from ₹0.15 loss in 2Q 2022). Revenue: ₹39.2m (up ₹39.1m from 2Q 2022). Net income: ₹1.23m (up ₹1.67m from 2Q 2022). Profit margin: 3.1% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Nov 05Crestchem Limited to Report Q2, 2023 Results on Nov 12, 2022Crestchem Limited announced that they will report Q2, 2023 results on Nov 12, 2022Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹81.10, the stock trades at a trailing P/E ratio of 41.7x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 479% over the past three years.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹52.50, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 257% over the past three years.Buying Opportunity • Aug 30Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be ₹51.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last 3 years. Meanwhile, the company has become profitable.Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹43.45, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 18x in the Chemicals industry in India. Total loss to shareholders of 15% over the past year.Buying Opportunity • Aug 10Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 1.9%. The fair value is estimated to be ₹51.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last 3 years. Meanwhile, the company has become profitable.Reported Earnings • Aug 02Full year 2022 earnings released: EPS: ₹1.89 (vs ₹1.91 in FY 2021)Full year 2022 results: EPS: ₹1.89 (down from ₹1.91 in FY 2021). Revenue: ₹79.5m (up 4.0% from FY 2021). Net income: ₹5.67m (down 1.2% from FY 2021). Profit margin: 7.1% (down from 7.5% in FY 2021). The decrease in margin was driven by higher expenses.お知らせ • Jul 29Crestchem Limited, Annual General Meeting, Aug 25, 2022Crestchem Limited, Annual General Meeting, Aug 25, 2022, at 12:15 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Accounts of the Company for the period (12 months) ended on 31st March 2022, and the Director's and Auditor's Reports thereon; to consider and, if thought fit, to pass with or without modification, the following Resolution as an Ordinary Resolution; and to consider any other business matters.Valuation Update With 7 Day Price Move • Jul 18Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹46.80, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 234% over the past three years.Reported Earnings • Jun 01Full year 2022 earnings released: EPS: ₹1.89 (vs ₹1.91 in FY 2021)Full year 2022 results: EPS: ₹1.89 (down from ₹1.91 in FY 2021). Revenue: ₹80.2m (up 5.0% from FY 2021). Net income: ₹5.67m (down 1.2% from FY 2021). Profit margin: 7.1% (down from 7.5% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 24Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹47.00, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 201% over the past three years.Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹50.00, the stock trades at a trailing P/E ratio of 26.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 251% over the past three years.Reported Earnings • Feb 10Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.72 (up from ₹0.18 in 3Q 2021). Revenue: ₹26.9m (up 123% from 3Q 2021). Net income: ₹2.15m (up 293% from 3Q 2021). Profit margin: 8.0% (up from 4.6% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Dec 14Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹39.05, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 18x in the Chemicals industry in India. Total loss to shareholders of 17% over the past year.Valuation Update With 7 Day Price Move • Nov 29Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹38.00, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 17x in the Chemicals industry in India. Total loss to shareholders of 42% over the past year.Reported Earnings • Oct 28Second quarter 2022 earnings released: ₹0.15 loss per share (vs ₹0.68 profit in 2Q 2021)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹217.0k (down 99% from 2Q 2021). Net loss: ₹446.0k (down 122% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Oct 26Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹39.40, the stock trades at a trailing P/E ratio of 18x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 243% over the past three years.Board Change • Sep 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Sep 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Sep 11Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Sep 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Sep 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Sep 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Sep 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Valuation Update With 7 Day Price Move • Aug 24Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹51.00, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 16x in the Chemicals industry in India. Total returns to shareholders of 343% over the past three years.Valuation Update With 7 Day Price Move • Jul 20Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹47.30, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 294% over the past three years.Reported Earnings • Jun 27Full year 2021 earnings released: EPS ₹1.91 (vs ₹1.48 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹76.4m (up 23% from FY 2020). Net income: ₹5.74m (up 29% from FY 2020). Profit margin: 7.5% (up from 7.2% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has only increased by 53% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jun 25Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹41.10, the stock trades at a trailing P/E ratio of 25.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 242% over the past three years.Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹38.15, the stock trades at a trailing P/E ratio of 23.4x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 218% over the past three years.Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹30.20, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 140% over the past three years.Is New 90 Day High Low • Mar 16New 90-day low: ₹26.95The company is down 43% from a price of ₹46.90 on 16 December 2020. Underperformed the Indian market, which is up 13% over the last 90 days. Lagged the Chemicals industry, which is up 8.0% over the same period.Valuation Update With 7 Day Price Move • Feb 12Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹28.60, the stock is trading at a trailing P/E ratio of 13.7x, down from the previous P/E ratio of 16.7x. This compares to an average P/E of 17x in the Chemicals industry in India. Total returns to shareholders over the past three years are 129%.お知らせ • Feb 05Crestchem Limited to Report Q3, 2021 Results on Feb 10, 2021Crestchem Limited announced that they will report Q3, 2021 results on Feb 10, 2021Is New 90 Day High Low • Feb 02New 90-day low: ₹33.95The company is down 33% from its price of ₹51.05 on 04 November 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period.Is New 90 Day High Low • Jan 17New 90-day low: ₹42.15The company is down 1.0% from its price of ₹42.50 on 19 October 2020. The Indian market is up 24% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period.株主還元526269IN ChemicalsIN 市場7D0.3%0.7%0.5%1Y-31.2%-2.6%-0.7%株主還元を見る業界別リターン: 526269過去 1 年間で-2.6 % の収益を上げたIndian Chemicals業界を下回りました。リターン対市場: 526269は、過去 1 年間で-0.7 % のリターンを上げたIndian市場を下回りました。価格変動Is 526269's price volatile compared to industry and market?526269 volatility526269 Average Weekly Movement9.9%Chemicals Industry Average Movement7.2%Market Average Movement7.2%10% most volatile stocks in IN Market10.1%10% least volatile stocks in IN Market4.8%安定した株価: 526269の株価は、 Indian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 526269の weekly volatility ( 10% ) は過去 1 年間安定していますが、依然としてIndianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19914Dipak Patelwww.crestchemlimited.inCrestchem Limited はインドで栄養化学製品の製造、販売、輸出を行っている。同社の製品には、中鎖トリグリセリド油脂パウダー、中鎖トリグリセリド油、スプレードライ脱脂粉乳、小児・成人用栄養製品、スプレードライ水溶性油脂パウダー（高油分ヒマワリ油、パーム油、ココナッツ油、乳製品クリーム、乳製品基材上の芳香族油パウダーなど）がある。同社は1991年に設立され、インドのアーメダバードを拠点としている。もっと見るCrestchem Limited 基礎のまとめCrestchem の収益と売上を時価総額と比較するとどうか。526269 基礎統計学時価総額₹390.00m収益（TTM）₹22.23m売上高(TTM)₹266.14m17.5xPER（株価収益率1.5xP/Sレシオ526269 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計526269 損益計算書（TTM）収益₹266.14m売上原価₹210.13m売上総利益₹56.01mその他の費用₹33.78m収益₹22.23m直近の収益報告Dec 31, 2025次回決算日May 26, 2026一株当たり利益（EPS）7.41グロス・マージン21.05%純利益率8.35%有利子負債／自己資本比率0%526269 の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.8%現在の配当利回り15%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 20:57終値2026/05/21 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Crestchem Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 18Crestchem Limited to Report Q4, 2026 Results on May 26, 2026Crestchem Limited announced that they will report Q4, 2026 results on May 26, 2026
Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹119, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 18% over the past three years.
New Risk • Apr 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$10m (₹233.3m market cap, or US$2.49m). Minor Risk Revenue is less than US$5m (₹266m revenue, or US$2.8m).
Recent Insider Transactions • Feb 27Chairman & MD recently bought ₹69k worth of stockOn the 23rd of February, Dipak Patel bought around 750 shares on-market at roughly ₹91.45 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹80k. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹533k worth in shares.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹2.39 (vs ₹1.74 in 3Q 2025)Third quarter 2026 results: EPS: ₹2.39 (up from ₹1.74 in 3Q 2025). Revenue: ₹73.4m (up 53% from 3Q 2025). Net income: ₹7.17m (up 38% from 3Q 2025). Profit margin: 9.8% (down from 11% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹95.46, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 49% over the past three years.
お知らせ • May 18Crestchem Limited to Report Q4, 2026 Results on May 26, 2026Crestchem Limited announced that they will report Q4, 2026 results on May 26, 2026
Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹119, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 18% over the past three years.
New Risk • Apr 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$10m (₹233.3m market cap, or US$2.49m). Minor Risk Revenue is less than US$5m (₹266m revenue, or US$2.8m).
Recent Insider Transactions • Feb 27Chairman & MD recently bought ₹69k worth of stockOn the 23rd of February, Dipak Patel bought around 750 shares on-market at roughly ₹91.45 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹80k. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹533k worth in shares.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹2.39 (vs ₹1.74 in 3Q 2025)Third quarter 2026 results: EPS: ₹2.39 (up from ₹1.74 in 3Q 2025). Revenue: ₹73.4m (up 53% from 3Q 2025). Net income: ₹7.17m (up 38% from 3Q 2025). Profit margin: 9.8% (down from 11% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹95.46, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 49% over the past three years.
お知らせ • Feb 07Crestchem Limited to Report Q3, 2026 Results on Feb 13, 2026Crestchem Limited announced that they will report Q3, 2026 results on Feb 13, 2026
New Risk • Feb 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹269.3m market cap, or US$2.98m). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Profit margins are more than 30% lower than last year (8.3% net profit margin). Revenue is less than US$5m (₹243m revenue, or US$2.7m).
Reported Earnings • Nov 14Second quarter 2026 earnings releasedSecond quarter 2026 results: Revenue: ₹73.4m (down 6.0% from 2Q 2025). Net income: ₹5.45m (down 45% from 2Q 2025). Profit margin: 7.4% (down from 13% in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 04Crestchem Limited to Report First Half, 2026 Results on Nov 12, 2025Crestchem Limited announced that they will report first half, 2026 results on Nov 12, 2025
お知らせ • Aug 06Crestchem Limited to Report Q1, 2026 Results on Aug 12, 2025Crestchem Limited announced that they will report Q1, 2026 results on Aug 12, 2025
Reported Earnings • Jul 31Full year 2025 earnings released: EPS: ₹9.09 (vs ₹7.15 in FY 2024)Full year 2025 results: EPS: ₹9.09 (up from ₹7.15 in FY 2024). Revenue: ₹250.8m (up 18% from FY 2024). Net income: ₹27.3m (up 27% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 60% per year whereas the company’s share price has increased by 59% per year.
Board Change • Jul 31High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Chairman & MD Dipak Patel is the most experienced director on the board, commencing their role in 2008. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 23+ 1 more updateCrestchem Limited Announces Resignation of Khyati Vyas as CFO, Effective July 1, 2025Crestchem Limited announced the resignation of Khyati Vyas as CFO with effect from July 01, 2025, due to her health problems.
お知らせ • Jun 24Crestchem Limited, Annual General Meeting, Aug 21, 2025Crestchem Limited, Annual General Meeting, Aug 21, 2025, at 12:15 Indian Standard Time.
Reported Earnings • May 29Full year 2025 earnings released: EPS: ₹9.09 (vs ₹7.15 in FY 2024)Full year 2025 results: EPS: ₹9.09 (up from ₹7.15 in FY 2024). Revenue: ₹255.2m (up 20% from FY 2024). Net income: ₹27.3m (up 27% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 60% per year whereas the company’s share price has increased by 58% per year.
お知らせ • May 28Crestchem Limited Recommends Final Dividend for the Financial Year Ended March 31, 2025Crestchem Limited recommended a final dividend at INR 1.00 (10%) per equity share of face value of INR 10 each for the financial year ended March 31, 2025. The said final dividend, if approved by the members of the Company at the upcoming Annual General Meeting (`AGM') of the Company, will be paid/dispatched within stipulated time period of its declaration at the said AGM of the Company.
お知らせ • May 20Crestchem Limited to Report Q4, 2025 Results on May 28, 2025Crestchem Limited announced that they will report Q4, 2025 results on May 28, 2025
Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹223, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 26x in the Chemicals industry in India. Total returns to shareholders of 433% over the past three years.
Recent Insider Transactions • Mar 23Chairman & MD recently bought ₹80k worth of stockOn the 21st of March, Dipak Patel bought around 350 shares on-market at roughly ₹230 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹829k worth in shares.
Valuation Update With 7 Day Price Move • Mar 06Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹216, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 441% over the past three years.
Reported Earnings • Feb 14Third quarter 2025 earnings released: EPS: ₹1.74 (vs ₹3.03 in 3Q 2024)Third quarter 2025 results: EPS: ₹1.74 (down from ₹3.03 in 3Q 2024). Revenue: ₹48.0m (down 35% from 3Q 2024). Net income: ₹5.21m (down 43% from 3Q 2024). Profit margin: 11% (down from 12% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹306, the stock trades at a trailing P/E ratio of 29x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 636% over the past three years.
お知らせ • Feb 04Crestchem Limited to Report Q3, 2025 Results on Feb 12, 2025Crestchem Limited announced that they will report Q3, 2025 results on Feb 12, 2025
Recent Insider Transactions • Jan 02Chairman & MD recently bought ₹61k worth of stockOn the 27th of December, Dipak Patel bought around 250 shares on-market at roughly ₹244 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹176k. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹742k worth in shares.
Valuation Update With 7 Day Price Move • Jan 01Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹294, the stock trades at a trailing P/E ratio of 35.2x. Average trailing P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 560% over the past three years.
Valuation Update With 7 Day Price Move • Nov 18Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹264, the stock trades at a trailing P/E ratio of 31.6x. Average trailing P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 476% over the past three years.
お知らせ • Oct 31Crestchem Limited to Report Q2, 2025 Results on Nov 12, 2024Crestchem Limited announced that they will report Q2, 2025 results on Nov 12, 2024
Valuation Update With 7 Day Price Move • Oct 25Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹226, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 508% over the past three years.
Valuation Update With 7 Day Price Move • Oct 10Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₹249, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 438% over the past three years.
Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹190, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 36x in the Chemicals industry in India. Total returns to shareholders of 257% over the past three years.
お知らせ • Sep 12Crestchem Limited Announces Resignation of Binaben Parasbhai Patel as Independent Director, Effective September 20, 2024Crestchem Limited announced resignation of Smt. Binaben Parasbhai Patel as Independent Director, w.e.f. September 20, 2024.
Reported Earnings • Aug 07Full year 2024 earnings released: EPS: ₹7.15 (vs ₹2.31 in FY 2023)Full year 2024 results: EPS: ₹7.15 (up from ₹2.31 in FY 2023). Revenue: ₹212.6m (up 27% from FY 2023). Net income: ₹21.5m (up 210% from FY 2023). Profit margin: 10% (up from 4.1% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 07Crestchem Limited to Report Q1, 2025 Results on Aug 12, 2024Crestchem Limited announced that they will report Q1, 2025 results at 12:15 PM, Indian Standard Time on Aug 12, 2024
Board Change • Jul 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Executive Independent Director Nitinkumar Shah was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Jul 10Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹144, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 161% over the past three years.
お知らせ • Jul 05Crestchem Limited Announces Director ChangesCrestchem Limited at its board meeting held on July 4, 2024 announced appointment of Smt. Priyanka M. Patel as additional director effective from July 4, 2024. Further, the company announced Resignation of Shri Manojkumar B. Patel as Independent Director effective from July 04, 2024, Due to his preoccupations. And Shri Rajesh I Mody ceased to be Independent Director effective from July 4, 2024 as his tenure as Independent director is over.
お知らせ • Jul 01Crestchem Limited, Annual General Meeting, Aug 30, 2024Crestchem Limited, Annual General Meeting, Aug 30, 2024.
Recent Insider Transactions • Jun 25Chairman & MD recently bought ₹53k worth of stockOn the 22nd of June, Dipak Patel bought around 388 shares on-market at roughly ₹136 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹300k. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹811k worth in shares.
Recent Insider Transactions • Jun 08Chairman & MD recently bought ₹300k worth of stockOn the 3rd of June, Dipak Patel bought around 2k shares on-market at roughly ₹143 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹758k worth in shares.
お知らせ • May 30Crestchem Limited Recommends Final Maiden Dividend for the Financial Year Ended March 31, 2024Crestchem Limited at its Board meeting held on May 28, 2024, recommended a final maiden dividend at INR 0.50 (5%) per equity share of face value of INR 10 each for the financial year ended March 31, 2024. The final dividend, if approved by the members of the company at the upcoming Annual General Meeting of the Company, will be paid/dispatched within stipulated time period of its declaration at the said AGM of the Company.
Reported Earnings • May 30Full year 2024 earnings released: EPS: ₹7.15 (vs ₹2.31 in FY 2023)Full year 2024 results: EPS: ₹7.15 (up from ₹2.31 in FY 2023). Revenue: ₹215.2m (up 29% from FY 2023). Net income: ₹21.5m (up 210% from FY 2023). Profit margin: 10.0% (up from 4.1% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 22Crestchem Limited to Report Q4, 2024 Results on May 28, 2024Crestchem Limited announced that they will report Q4, 2024 results on May 28, 2024
Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹105, the stock trades at a trailing P/E ratio of 20.3x. Average trailing P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 277% over the past three years.
Reported Earnings • Feb 14Third quarter 2024 earnings released: EPS: ₹3.03 (vs ₹0.72 in 3Q 2023)Third quarter 2024 results: EPS: ₹3.03 (up from ₹0.72 in 3Q 2023). Revenue: ₹74.2m (up 85% from 3Q 2023). Net income: ₹9.09m (up 322% from 3Q 2023). Profit margin: 12% (up from 5.4% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Nov 17Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹80.60, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 28% over the past three years.
Reported Earnings • Nov 05Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: ₹45.5m (up 17% from 2Q 2023). Net income: ₹3.39m (up 176% from 2Q 2023). Profit margin: 7.5% (up from 3.2% in 2Q 2023). The increase in margin was driven by higher revenue.
お知らせ • Oct 28Crestchem Limited to Report Q2, 2024 Results on Nov 04, 2023Crestchem Limited announced that they will report Q2, 2024 results on Nov 04, 2023
Recent Insider Transactions • Sep 24Chairman & MD recently bought ₹111k worth of stockOn the 22nd of September, Dipak Patel bought around 2k shares on-market at roughly ₹62.47 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹116k. Despite this recent buy, Dipak has been a net seller over the last 12 months, reducing personal holdings by ₹152k.
お知らせ • Aug 05Crestchem Limited to Report Q1, 2024 Results on Aug 12, 2023Crestchem Limited announced that they will report Q1, 2024 results on Aug 12, 2023
Reported Earnings • Jul 30Full year 2023 earnings released: EPS: ₹2.31 (vs ₹1.89 in FY 2022)Full year 2023 results: EPS: ₹2.31 (up from ₹1.89 in FY 2022). Revenue: ₹168.8m (up 112% from FY 2022). Net income: ₹6.93m (up 22% from FY 2022). Profit margin: 4.1% (down from 7.1% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 83% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 07Crestchem Limited, Annual General Meeting, Aug 24, 2023Crestchem Limited, Annual General Meeting, Aug 24, 2023, at 12:15 Indian Standard Time.
Valuation Update With 7 Day Price Move • Jun 01Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹88.04, the stock trades at a trailing P/E ratio of 35.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 91% over the past year.
Valuation Update With 7 Day Price Move • May 18Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹80.65, the stock trades at a trailing P/E ratio of 32.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 95% over the past year.
Valuation Update With 7 Day Price Move • Apr 19Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹101, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 863% over the past three years.
Recent Insider Transactions • Mar 23Chairman & MD recently sold ₹226k worth of stockOn the 21st of March, Dipak Patel sold around 2k shares on-market at roughly ₹98.48 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Dipak has been a net seller over the last 12 months, reducing personal holdings by ₹378k.
Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹112, the stock trades at a trailing P/E ratio of 44.7x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 917% over the past three years.
Recent Insider Transactions • Mar 13Chairman & MD recently sold ₹166k worth of stockOn the 10th of March, Dipak Patel sold around 2k shares on-market at roughly ₹91.88 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Dipak has been a net seller over the last 12 months, reducing personal holdings by ₹152k.
Valuation Update With 7 Day Price Move • Mar 08Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹83.83, the stock trades at a trailing P/E ratio of 33.5x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 629% over the past three years.
Valuation Update With 7 Day Price Move • Feb 16Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹74.95, the stock trades at a trailing P/E ratio of 29.9x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 552% over the past three years.
お知らせ • Jan 31Crestchem Limited to Report Q3, 2023 Results on Feb 11, 2023Crestchem Limited announced that they will report Q3, 2023 results on Feb 11, 2023
Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹0.41 (vs ₹0.15 loss in 2Q 2022)Second quarter 2023 results: EPS: ₹0.41 (up from ₹0.15 loss in 2Q 2022). Revenue: ₹39.2m (up ₹39.1m from 2Q 2022). Net income: ₹1.23m (up ₹1.67m from 2Q 2022). Profit margin: 3.1% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Nov 05Crestchem Limited to Report Q2, 2023 Results on Nov 12, 2022Crestchem Limited announced that they will report Q2, 2023 results on Nov 12, 2022
Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹81.10, the stock trades at a trailing P/E ratio of 41.7x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 479% over the past three years.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹52.50, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 257% over the past three years.
Buying Opportunity • Aug 30Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be ₹51.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last 3 years. Meanwhile, the company has become profitable.
Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹43.45, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 18x in the Chemicals industry in India. Total loss to shareholders of 15% over the past year.
Buying Opportunity • Aug 10Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 1.9%. The fair value is estimated to be ₹51.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last 3 years. Meanwhile, the company has become profitable.
Reported Earnings • Aug 02Full year 2022 earnings released: EPS: ₹1.89 (vs ₹1.91 in FY 2021)Full year 2022 results: EPS: ₹1.89 (down from ₹1.91 in FY 2021). Revenue: ₹79.5m (up 4.0% from FY 2021). Net income: ₹5.67m (down 1.2% from FY 2021). Profit margin: 7.1% (down from 7.5% in FY 2021). The decrease in margin was driven by higher expenses.
お知らせ • Jul 29Crestchem Limited, Annual General Meeting, Aug 25, 2022Crestchem Limited, Annual General Meeting, Aug 25, 2022, at 12:15 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Accounts of the Company for the period (12 months) ended on 31st March 2022, and the Director's and Auditor's Reports thereon; to consider and, if thought fit, to pass with or without modification, the following Resolution as an Ordinary Resolution; and to consider any other business matters.
Valuation Update With 7 Day Price Move • Jul 18Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹46.80, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 234% over the past three years.
Reported Earnings • Jun 01Full year 2022 earnings released: EPS: ₹1.89 (vs ₹1.91 in FY 2021)Full year 2022 results: EPS: ₹1.89 (down from ₹1.91 in FY 2021). Revenue: ₹80.2m (up 5.0% from FY 2021). Net income: ₹5.67m (down 1.2% from FY 2021). Profit margin: 7.1% (down from 7.5% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 24Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹47.00, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 201% over the past three years.
Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹50.00, the stock trades at a trailing P/E ratio of 26.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 251% over the past three years.
Reported Earnings • Feb 10Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.72 (up from ₹0.18 in 3Q 2021). Revenue: ₹26.9m (up 123% from 3Q 2021). Net income: ₹2.15m (up 293% from 3Q 2021). Profit margin: 8.0% (up from 4.6% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Dec 14Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹39.05, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 18x in the Chemicals industry in India. Total loss to shareholders of 17% over the past year.
Valuation Update With 7 Day Price Move • Nov 29Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₹38.00, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 17x in the Chemicals industry in India. Total loss to shareholders of 42% over the past year.
Reported Earnings • Oct 28Second quarter 2022 earnings released: ₹0.15 loss per share (vs ₹0.68 profit in 2Q 2021)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹217.0k (down 99% from 2Q 2021). Net loss: ₹446.0k (down 122% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Oct 26Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹39.40, the stock trades at a trailing P/E ratio of 18x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 243% over the past three years.
Board Change • Sep 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Sep 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Sep 11Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Sep 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Sep 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Sep 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Sep 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Aug 24Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹51.00, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 16x in the Chemicals industry in India. Total returns to shareholders of 343% over the past three years.
Valuation Update With 7 Day Price Move • Jul 20Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹47.30, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 294% over the past three years.
Reported Earnings • Jun 27Full year 2021 earnings released: EPS ₹1.91 (vs ₹1.48 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹76.4m (up 23% from FY 2020). Net income: ₹5.74m (up 29% from FY 2020). Profit margin: 7.5% (up from 7.2% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has only increased by 53% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jun 25Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹41.10, the stock trades at a trailing P/E ratio of 25.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 242% over the past three years.
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹38.15, the stock trades at a trailing P/E ratio of 23.4x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 218% over the past three years.
Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹30.20, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 140% over the past three years.
Is New 90 Day High Low • Mar 16New 90-day low: ₹26.95The company is down 43% from a price of ₹46.90 on 16 December 2020. Underperformed the Indian market, which is up 13% over the last 90 days. Lagged the Chemicals industry, which is up 8.0% over the same period.
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹28.60, the stock is trading at a trailing P/E ratio of 13.7x, down from the previous P/E ratio of 16.7x. This compares to an average P/E of 17x in the Chemicals industry in India. Total returns to shareholders over the past three years are 129%.
お知らせ • Feb 05Crestchem Limited to Report Q3, 2021 Results on Feb 10, 2021Crestchem Limited announced that they will report Q3, 2021 results on Feb 10, 2021
Is New 90 Day High Low • Feb 02New 90-day low: ₹33.95The company is down 33% from its price of ₹51.05 on 04 November 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period.
Is New 90 Day High Low • Jan 17New 90-day low: ₹42.15The company is down 1.0% from its price of ₹42.50 on 19 October 2020. The Indian market is up 24% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period.
